Genmab Beheer

Beheer criteriumcontroles 3/4

De CEO Genmab is Jan G.J. de Winkel, benoemd in Jun2010, heeft een ambtstermijn van 14.42 jaar. De totale jaarlijkse vergoeding van { bedraagt DKK 44.30M, bestaande uit 20.8% salaris en 79.2% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.99% van de aandelen van het bedrijf, ter waarde DKK 914.35M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 7.4 jaar en 7.7 jaar.

Belangrijke informatie

Jan G.J. de Winkel

Algemeen directeur

DKK 44.3m

Totale compensatie

Percentage CEO-salaris	20.8%
Dienstverband CEO	14.4yrs
Eigendom CEO	1.0%
Management gemiddelde ambtstermijn	7.4yrs
Gemiddelde ambtstermijn bestuur	7.7yrs

Recente managementupdates

We Think Genmab A/S' (CPH:GMAB) CEO Compensation Package Needs To Be Put Under A Microscope

Mar 07

Recent updates

We Think Genmab A/S' (CPH:GMAB) CEO Compensation Package Needs To Be Put Under A Microscope

Mar 07

Genmab's (CPH:GMAB) Conservative Accounting Might Explain Soft Earnings

Feb 21

Is Genmab A/S (CPH:GMAB) Trading At A 50% Discount?

Nov 13

Is Now The Time To Put Genmab (CPH:GMAB) On Your Watchlist?

Jun 19

Is There An Opportunity With Genmab A/S' (CPH:GMAB) 44% Undervaluation?

May 29

With EPS Growth And More, Genmab (CPH:GMAB) Makes An Interesting Case

Mar 18

Genmab A/S (CPH:GMAB) Shares Could Be 50% Below Their Intrinsic Value Estimate

Feb 27

Here's Why We Think Genmab (CPH:GMAB) Is Well Worth Watching

Dec 17

Analyse CEO-vergoeding

Hoe is Jan G.J. de Winkel's beloning veranderd ten opzichte van Genmab's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	DKK 5b
Jun 30 2024	n/a	n/a	DKK 6b
Mar 31 2024	n/a	n/a	DKK 5b
Dec 31 2023	DKK 44m	DKK 9m	DKK 4b
Sep 30 2023	n/a	n/a	DKK 4b
Jun 30 2023	n/a	n/a	DKK 5b
Mar 31 2023	n/a	n/a	DKK 5b
Dec 31 2022	DKK 42m	DKK 9m	DKK 5b
Sep 30 2022	n/a	n/a	DKK 6b
Jun 30 2022	n/a	n/a	DKK 4b
Mar 31 2022	n/a	n/a	DKK 2b
Dec 31 2021	DKK 38m	DKK 8m	DKK 3b
Sep 30 2021	n/a	n/a	DKK 3b
Jun 30 2021	n/a	n/a	DKK 3b
Mar 31 2021	n/a	n/a	DKK 6b
Dec 31 2020	DKK 37m	DKK 7m	DKK 5b
Sep 30 2020	n/a	n/a	DKK 6b
Jun 30 2020	n/a	n/a	DKK 6b
Mar 31 2020	n/a	n/a	DKK 2b
Dec 31 2019	DKK 35m	DKK 7m	DKK 2b
Sep 30 2019	n/a	n/a	DKK 2b
Jun 30 2019	n/a	n/a	DKK 1b
Mar 31 2019	n/a	n/a	DKK 1b
Dec 31 2018	DKK 28m	DKK 7m	DKK 1b
Sep 30 2018	n/a	n/a	DKK 1b
Jun 30 2018	n/a	n/a	DKK 1b
Mar 31 2018	n/a	n/a	DKK 1b
Dec 31 2017	DKK 27m	DKK 7m	DKK 1b

Compensatie versus markt: De totale vergoeding ($USD 6.25M ) Jan G.J. } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de Danish markt ($USD 3.68M ).

Compensatie versus inkomsten: De vergoeding van Jan G.J. is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Jan G.J. de Winkel (63 yo)

14.4yrs

Tenure

DKK 44,300,000

Compensatie

Dr. Jan G.J. van de Winkel, Ph.D. was Independent Director of HOOKIPA Pharma Inc. from 2023 until August 30, 2024 and served as Chairman of the Board since 2024 August 30, 2024. Dr. Winkel served as a Memb...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Jan G.J. de Winkel	Co-Founder	14.4yrs	DKK 44.30m	0.99% DKK 914.4m
Anthony Pagano	Executive VP & CFO	4.7yrs	DKK 19.60m	0.011% DKK 10.2m
Birgitte Stephensen	Executive VP & Chief Legal Officer	14.8yrs	DKK 10.10m	geen gegevens
Christopher Cozic	Executive VP & Chief People Officer	7yrs	DKK 13.20m	geen gegevens
Martine van Vugt	Executive VP & Chief Strategy Officer	10.8yrs	DKK 8.90m	geen gegevens
Martin Schultz	Senior Director of Clinical Operations & Non-Independent Director	no data	DKK 800.00k	0.00061% DKK 561.8k
Judith Klimovsky	Executive VP & Chief Development Officer	7.8yrs	DKK 21.70m	0.014% DKK 12.7m
Tahamtan Ahmadi	Executive VP	3.7yrs	DKK 19.80m	0.0049% DKK 4.5m
Mijke Zachariasse	Senior Director	no data	DKK 1.10m	0.00083% DKK 764.4k
Takahiro Hamatani	Senior Director of Finance Japan & Non-Independent Director	no data	DKK 800.00k	0.00013% DKK 119.7k
Rayne Waller	Executive VP & CTO	less than a year	geen gegevens	geen gegevens
Andrew Carlsen	Senior Director	no data	geen gegevens	geen gegevens

7.4yrs

Gemiddelde duur

50.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van GMAB is doorgewinterd en ervaren (gemiddelde ambtstermijn van 7.4 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Martin Schultz	Senior Director of Clinical Operations & Non-Independent Director	2.8yrs	DKK 800.00k	0.00061% DKK 561.8k
Mijke Zachariasse	Senior Director	5.7yrs	DKK 1.10m	0.00083% DKK 764.4k
Takahiro Hamatani	Senior Director of Finance Japan & Non-Independent Director	2.8yrs	DKK 800.00k	0.00013% DKK 119.7k
Anders Pedersen	Non-Independent Director	21yrs	DKK 1.70m	0.011% DKK 10.6m
Elizabeth O'Farrell	Independent Director	2.7yrs	DKK 1.90m	geen gegevens
Deirdre Connelly	Independent Chairman of the Board	7.7yrs	DKK 2.80m	0.0091% DKK 8.3m
Rolf Hoffmann	Independent Director	7.7yrs	DKK 1.50m	0.0053% DKK 4.9m
Pernille Erenbjerg	Independent Deputy Chairman	9.8yrs	DKK 2.10m	0.0076% DKK 7.0m
Paolo Paoletti	Independent Director	9.8yrs	DKK 1.50m	0.0033% DKK 3.0m

7.7yrs

Gemiddelde duur

59yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van GMAB wordt beschouwd als ervaren (gemiddelde ambtstermijn 7.7 jaar).

Genmab Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Genmab A/S Announces Executive Changes

Co-Founder exercised options to buy kr.45m worth of stock.

Non-Independent Director recently sold kr.3.8m worth of stock

Genmab A/S Announces Executive Changes

We Think Genmab A/S' (CPH:GMAB) CEO Compensation Package Needs To Be Put Under A Microscope

Executive VP & CFO recently sold kr.22m worth of stock

Recent updates

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

The Price Is Right For Genmab A/S (CPH:GMAB)

Genmab Announces New Data from the Phase 1/2 Study Of Rinatabart Sesutecan (Rina-S), an Investigational Folate Receptor-Alpha (FRa)-Targeted, Topo1 Antibody-Drug Conjugate

We Think Genmab's (CPH:GMAB) Solid Earnings Are Understated

Genmab A/S Receives Second European Commission Approval for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma

Genmab A/S Announces Executive Changes

Co-Founder exercised options to buy kr.45m worth of stock.

Second quarter 2024 earnings released: EPS: kr.21.85 (vs kr.20.46 in 2Q 2023)

Consensus EPS estimates fall by 15%

Genmab A/S Takes Full Control of Acasunlimab Development Program

Consensus EPS estimates increase by 14%

Genmab A/S Announces That the U.S. Food and Drug Administration Approved Epkinly® (Epcoritamab-Bysp) for the Treatment of Adults with Relapsed or Refractory Follicular Lymphoma After Two or More Lines of Systemic EPKINLY

Non-Independent Director recently sold kr.3.8m worth of stock

Genmab A/S Announces New Efficacy and Safety Data from Two Ongoing Phase 1/2 Clinical Trials Evaluating Epcoritamab, A T-Cell Engaging Bispecific Antibody Administered Subcutaneously, in Adult Patients with Certain Types of Follicular Lymphoma

Genmab A/S (CPSE:GMAB) completed the acquisition of ProfoundBio, Inc.

Genmab A/S to Present New and Updated Results from Multiple Clinical Trials Evaluating Epcoritamab Across Various B-Cell Malignancies At the 2024 European Hematology Association (Eha) Congress

Consensus EPS estimates fall by 11%

First quarter 2024 earnings released: EPS: kr.20.29 (vs kr.3.46 in 1Q 2023)

Pfizer Inc. and Genmab A/S Announce FDA Grants Full Approval for TIVDAK to Treat Recurrent or Metastatic Cervical Cancer

Genmab A/S (CPSE:GMAB) entered into a definitive agreement to acquire ProfoundBio for $1.8 billion.

Genmab A/S (CPSE:GMAB) entered into a definitive agreement to acquire ProfoundBio for $1.8 billion.

Genmab A/S' (CPH:GMAB) Price In Tune With Earnings

Genmab A/S Announces Executive Changes

We Think Genmab A/S' (CPH:GMAB) CEO Compensation Package Needs To Be Put Under A Microscope

Executive VP & CFO recently sold kr.22m worth of stock

Executive VP & CFO exercised options to buy kr.22m worth of stock.

Genmab A/S and AbbVie Announce U.S. Food and Drug Administration Grants Priority Review for the Supplemental Biologics License Application for Epcoritamab (Epkinly®) for Difficult-To-Treat Relapsed or Refractory Follicular Lymphoma

Genmab's (CPH:GMAB) Conservative Accounting Might Explain Soft Earnings

Full year 2023 earnings: EPS misses analyst expectations

Genmab A/S and Pfizer, Inc. Announces Validation for Review the Marketing Authorization Application of Tivdak®?

Genmab A/S Announces Decision in Arbitration Appeal Under License Agreement with Janssen Biotech, Inc

Pfizer Inc. and Genmab A/S Announce U.S. Food and Drug Administration Accepts TIVDAK® Supplemental Biologics License Application

Genmab A/S and AbbVie Announces New Pivotal Data for Bispecific Antibody Epcoritamab (Duobody CD3xCD20) Demonstrates High Overall and Complete Responses in Patients with Hard-To-Treat Relapsed/Refractory Follicular Lymphoma

Genmab A/S Announces Positive Regulatory Updates for Epcoritamab (EPKINLY®?/TEPKINLY®?) for the Treatment of Relapsed/Refractory Follicular Lymphoma

Genmab A/S Announces Positive Regulatory Updates for Epcoritamab (EPKINLY®?/TEPKINLY®?) for the Treatment of Relapsed/Refractory Follicular Lymphoma

Is Genmab A/S (CPH:GMAB) Trading At A 50% Discount?

Genmab A/S Revises Earnings Guidance for the Year 2023

Third quarter 2023 earnings released: EPS: kr.32.60 (vs kr.39.55 in 3Q 2022)

Genmab A/S, Annual General Meeting, Mar 13, 2024

Genmab A/S to Report Q1, 2024 Results on May 02, 2024

Genmab A/S and Seagen Inc. Announce Additional Results from the Phase 3 innovaTV 301 Randomized Global Trial

Investor sentiment deteriorates as stock falls 16%

Genmab A/S Announces European Commission Approval of Tepkinly(R) (epcoritamab) for Adults with Relapsed Or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Seagen Inc. and Genmab A/S Announce That Tivdak(R) (Tisotumab Vedotin-Tftv) Met Its Primary Endpoint of Improved Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared to Chemotherapy

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Genmab A/S Revises Earning Guidance for the Year 2023

Genmab A/S Announces AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY(R) Diffuse Large B-Cell Lymphoma

AbbVie and Genmab Announce Positive Topline Results from Phase 1/2 EPCORE™ NHL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)

Genmab A/S Announces Epcoritamab Added to National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology for ‘B-Cell Lymphomas’

Is Now The Time To Put Genmab (CPH:GMAB) On Your Watchlist?

Genmab A/S Showcases Data from Comprehensive Epcoritamab Development Program in Patients Across B-Cell Lymphomas At European Hematology Association (EHA) Annual Meeting 2023

Co-Founder recently sold kr.58m worth of stock

Is There An Opportunity With Genmab A/S' (CPH:GMAB) 44% Undervaluation?

U.S. Food and Drug Administration Approves Genmab A/S’s EPKINLY (epcoritamab-bysp) as the First and Only Bispecific Antibody to Treat Adults with Relapsed or Refractory Diffuse Large B-cell Lymphoma

Genmab A/S Provides Earnings Guidance for 2023

First quarter 2023 earnings released: EPS: kr.3.46 (vs kr.7.10 in 1Q 2022)

Independent Chairman of the Board recently bought kr.796k worth of stock

With EPS Growth And More, Genmab (CPH:GMAB) Makes An Interesting Case

Genmab A/S (CPH:GMAB) Shares Could Be 50% Below Their Intrinsic Value Estimate

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Insufficient new directors

Genmab A/S Announces Submission of Japan New Drug Application for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma

Here's Why We Think Genmab (CPH:GMAB) Is Well Worth Watching

Co-Founder recently sold kr.57m worth of stock

Genmab A/S Showcases Data From Robust Development Program Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients Across a Broad Range of B-Cell Lymphomas at the 64th Annual ASH Meeting

Genmab A/S to Report Nine Months, 2023 Results on Nov 07, 2023

Analyse CEO-vergoeding

CEO

Tenure